Kailera Therapeutics (NASDAQ:KLRA) Stock Price Up 8.3% - Time to Buy?

Key Points

• Kailera Therapeutics shares rose 8.3% to $12.38 in midday trading, though volume was 72% below the average session level.
• Analysts collectively rate the stock “Moderate Buy” with an average price target of $42.75, but Weiss Ratings downgraded it further to “sell (d-).”
• The clinical-stage obesity and metabolic-disease company reported a quarterly EPS loss of $1.09, missing estimates by $0.35; analysts expect a full-year loss of $3.89 per share.

Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report)'s stock price traded up 8.3% during mid-day trading on Tuesday. The stock traded as high as $12.51 and last traded at $12.38. 239,776 shares were traded during mid-day trading, a decline of 72% from the average session volume of 869,952 shares. The stock had previously closed at $11.43.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Kailera Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a report on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $42.75.

Kailera Therapeutics Stock Performance

The firm has a market capitalization of $1.68 billion and a PE ratio of -0.00. The stock has a fifty day simple moving average of $14.18.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, sell-side analysts forecast that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Investors Weigh In On Kailera Therapeutics

Several large investors have recently bought and sold shares of the business. Tidal Investments LLC bought a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at about $309,000. Squarepoint Ops LLC purchased a new stake in shares of Kailera Therapeutics in the second quarter valued at approximately $993,000. Mirador Capital Partners LP purchased a new stake in Kailera Therapeutics in the 3rd quarter valued at about $666,000. State Street Corp purchased a new stake in Kailera Therapeutics during the 2nd quarter worth approximately $19,126,000. Finally, Frazier Life Sciences Management L.P. acquired a new stake in shares of Kailera Therapeutics during the 2nd quarter worth about $24,233,000.

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company's research is centered on therapies designed to address weight management and related health conditions.

Kailera's pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.